BHC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BH

Mkt Cap

$2.36B

Volume

1.75M

Next Earnings

October 28th

Loading chart

BH

BHCBausch Health Companies Inc

BHC

Pay with—

Available Balance0.00

BH

Mkt Cap

$2.36B

Volume

1.75M

Next Earnings

October 28th

Chart Financials Earnings News About Insider Filings

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate HikeWith Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.Zacks Investment Research · Oct 2, 2026

Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 PicksConsumer confidence fell 6.7% to 81.9 in September 2026, hitting its lowest level since April 2014, driven by concerns about labor market conditions and Middle East geopolitical tensions. The Federal Reserve hiked interest rates by 25 basis points and hinted at further increases. In response, four defensive stocks from healthcare and consumer staples sectors are recommended: Bausch Health Companies, CareDx, Dole, and The Chefs' Warehouse.Zacks Investment Research · Sep 30, 2026

Acne Vulgaris Market Set for Significant Growth During the Forecast Period (2026–2036), Amid Rising Disease Burden and Therapeutic Advances | DelveInsightThe acne vulgaris market is expected to grow steadily through 2036, driven by increasing disease prevalence affecting 85% of adolescents and young adults, and a pipeline of emerging therapies. Key players including Ascletis Pharma, Sagimet Biosciences, AOB Pharma, and Kintor Pharmaceutical are developing novel treatments like Denifanstat (ASC40), TVB-3567, B244, and GT20029 to address unmet needs in moderate-to-severe and treatment-resistant acne. The U.S. holds the largest market share, with recent approvals including clascoterone (WINLEVI) and combination therapy CABTREO expanding treatment options.GlobeNewswire Inc. · Sep 28, 2026

Body Contouring Devices Market Expands as Non-Invasive Technology Reaches Untapped Male DemographicThe global body contouring devices market is expected to grow from $2.41 billion in 2025 to $8.82 billion by 2035, with a CAGR of 13.84%. Non-invasive treatments dominate with 78.4% market share, driven by rising obesity rates and increasing demand for non-surgical aesthetic procedures. The U.S. market alone is projected to reach $2.74 billion by 2035. Key growth drivers include expanding male demographics, multi-modal technology platforms, and rising social media influence on aesthetic awareness.GlobeNewswire Inc. · Sep 19, 2026

4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate HikeWith inflation remaining stubbornly high at 3.4% annually and a 90% probability of a Federal Reserve rate hike expected, the article recommends four defensive healthcare stocks: Amgen, Bausch Health, CareDx, and Centene. CareDx and Centene are expected to deliver over 100% earnings growth this year, while all four stocks have seen improved earnings estimates over the past 60 days.Zacks Investment Research · Sep 14, 2026

Why Bausch Health Companies Stock Skyrocketed by Almost 40% Last MonthBausch Health Companies stock surged nearly 40% in July 2026, driven by a regulatory win in Canada for its Prokedi schizophrenia drug and a strong Q2 earnings beat. The company reported $2.85 billion in revenue (13% YoY growth) and adjusted net income of $476 million ($1.26 per share), exceeding analyst expectations. Management raised full-year 2026 guidance for both revenue and adjusted EBITDA, citing strength across its diversified pharmaceutical portfolio.The Motley Fool · Aug 10, 2026

Hepatic Encephalopathy Market Set for Growth at a 1.2% CAGR Through 2036, Driven by Emerging Therapies and Rising Disease Burden | DelveInsightThe hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market share, with approximately 210,000 prevalent cases across the 7MM in 2025.GlobeNewswire Inc. · May 4, 2026

Why Bausch Health Companies Was Crawling Higher This WeekBausch Health Companies reported Q1 2026 earnings that beat analyst expectations with $2.52 billion in revenue (up 12% YoY) and non-GAAP net income of $0.78 per share (up 35% YoY), exceeding consensus estimates of $2.42 billion and $0.68 per share respectively. The company maintained its full-year 2026 guidance and highlighted 12 consecutive quarters of revenue growth, driving the stock up nearly 2% for the week.The Motley Fool · May 1, 2026

Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsightThe pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.GlobeNewswire Inc. · Apr 20, 2026

Dermatology Devices Market to Reach $25.6 Billion by 2030, Driven by Rising Skin Cancer Incidence and Aesthetic DemandThe global dermatology devices market is projected to grow from $14.4 billion in 2024 to $25.6 billion by 2030, with a CAGR of 10.4%. Growth is driven by rising skin cancer incidence, aging populations, aesthetic procedure demand, and technological innovations including picosecond lasers and 3D bioprinting. North America leads with 52.3% market share.GlobeNewswire Inc. · Apr 13, 2026

to start trading

BH

BHCBausch Health Companies Inc

BHC

Pay with—

Available Balance0.00

Your PositionYou don't own any BHC yet.

Related Tickers

Earnings